Cargando…
Advanced Nanomedicine for High-Risk HPV-Driven Head and Neck Cancer
The incidence of high-risk Human Papillomavirus (HR-HPV)-driven head and neck squamous cell carcinoma (HNSCC) is on the rise globally. HR-HPV-driven HNSCC displays molecular and clinical characteristics distinct from HPV-uninvolved cases. Therapeutic strategies for HR-HPV-driven HNSCC are under inve...
Autores principales: | Xu, Qiang, Chen, Ye, Jin, Yuan, Wang, Zhiyu, Dong, Haoru, Kaufmann, Andreas M., Albers, Andreas E., Qian, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788019/ https://www.ncbi.nlm.nih.gov/pubmed/36560828 http://dx.doi.org/10.3390/v14122824 |
Ejemplares similares
-
Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck
por: Xu, Qiang, et al.
Publicado: (2020) -
Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care
por: Dong, Haoru, et al.
Publicado: (2021) -
Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients
por: Qian, Xu, et al.
Publicado: (2019) -
Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety
por: Qian, Xu, et al.
Publicado: (2015) -
A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment
por: Chen, Chao, et al.
Publicado: (2010)